In addition to a role in tumor initiation, it appears that KRAS activation is required for maintenance of the tumorigenic growth of established PDAC, since disruption of KRAS activity—via RNA interference, antisense RNA, or expression of dominant-negative KRASN17—attenuates the tumorigenicity of PDAC cell lines [23]. The gene discussed is KRAS; the disease is neoplasm.